- BioCryst (BCRX) continues to work towards finding novel treatment options for HAE, as the company advances two optimized plasma kallikrein inhibitors into preclinicals.
- The two candidates improved selectivity and bioavailability compared to BCX-4161 with "no effect on prothrombin time at high concentrations." (PR)
- BCRX +7.5% premarket
at Zacks.com (Nov 10, 2014)